Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol
Xiangdong Cheng(Hangzhou Cancer Hospital), Yunli Zhang(Zhejiang Cancer Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Yunhai Wei(Huzhou Central Hospital), Zhiyuan Xu(Zhejiang Cancer Hospital), Zhilong Yan(Ningbo University), Ping Chen(Central South University), Wei Li(Jilin University), Wenming Feng(Huzhou University), Yian Du(Zhejiang Cancer Hospital), Lei Zhou(China-Japan Friendship Hospital), Chang Wang(Jilin University), Nong Xu(Zhejiang University), Luchuan Chen(Fujian Medical University), Jianfa Yu(Zhejiang Provincial Hospital of TCM), Litao Yang(Zhejiang Cancer Hospital), Dan Wu(Nanjing Drum Tower Hospital), Pengfei Yu(Suzhou Traditional Chinese Medicine Hospital), Jiuwei Cui(Jilin University)
Cited by 14
Related Papers
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|Annals of Oncology|2019|475
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
|Biomarker Research|2020|473